David Schaer Phd Email & Phone Number

Leverkusen, North Rhine-Westphalia, De

Senior Director – Bayer Science Fellow – Translational Science Lead DGK programPrecision Medicine Lead – Immuno-oncology, Research and Early Development Oncology- Translational Science Lead for DGK program • Single point of contact to Integrated Project team for DGK zeta and DGK alpha projects, assuring integration of all translational aspect from biomarker, clinical pharmacology, computational biology, and leading strategic planning- Bayer Representative and Industry Co-Lead of IMMUcan – Multi-Modality Tumor Microenvironment Profiling IMI2 consortium- Translational Sciences representative on IO related business development and licensing evaluation

New York, New York, Us

Director - Translational Oncology Lead - Oncology Translational Research – Translational Sciences Group, Oncology Research and Development Member of core teams for clinical assets in early phase trials including solid tumor bi-specific T cell engagers, TGF beta large and small molecule targeting agents and checkpoint inhibitor bi-specifics • Support and contribute to development plans for both clinical and preclinical programs• Plan and implement clinical biomarker plans to help demonstrate proof of mechanism in early phase clinical trials• Work with discovery groups during in project development to facilitate early biomarker research• Interface with KOLs and clinical investigators to establish clinical research collaborations and as part of scientific advisory boards and trial outreach

Indianapolis, Indiana, Us

Experimental and Translational Immuno-Oncology GroupLead Scientist; Combination Immunotherapy & TIM3., TIM3/PD-L1 Bispecific Clinical Program• Established workflow for combination immunotherapy research at Eli Lilly for IO+IO and IO + Non-IO compounds to enable screening and translation of promising combinations• Implemented standardized Immune Landscape Analysis application of multidimensional biomarker platforms as general approach to in vivo experimentsPrior responsibilities: Lead Scientist CSF-1R Clinical Program, Biologist on TGFb pathway

New York, Ny, Us

Project Lead: 4-Antibody / Ludwig Inst. for Cancer Research / MSKCC CollaborationImmuno-Oncology Clinical Biomarker and Drug DiscoveryClinical biomarker discovery responsibilities:• Development of ex-vivo assays and SOPs to measure effects of agonistic co-stimulatory and antagonistic co-inhibitory immunotherapyDrug discovery responsibilities:• Design and implementation of in-vitro assays for identification of immunomodulatory drug candidates• Identified lead agonistic (GITR, OX40) and antagonistic (CTLA-4, PD-1) antibody drug candidates which entered clinical testing beginning in 2016 (GITR: NCT02697591, CTLA4: NCT02694822, April 2016, OX40: NCT02923349, October 2016, PD-1 NCT03104699, Mar 2017)

New York, Ny, Us

Main Projects• Determine the mechanisms of GITR targeted co-stimulatory tumor immunotherapy • Examine the cause of intra-tumor immune suppression and effects of immuno-modulation in preclinical melanoma models through intravital imaging and ex-vivo analysisCollaborations:• Investigate use of novel multivalent silica particles combined with anti-TYRP1 antibodies as tracers for lymphatic drainage and metastatic melanoma burden in preclinical and clinical settings • Effect of tumor stroma on critical adoptive T cell concentration required for sterilizing tumoricidal activity

PhD thesis: T Cell Receptor Signaling Defects Abrogate Lytic Function in CD8+ Tumor Infiltrating Lymphocytes

New York, Ny, Us

Assisted research on the role of dendritic cells in the pathogenesis of SIV infection as a model for HIV

Phd, Biomedical Sciences, Molecular Oncology And Immunology Training Program

Bs, Biology With High Honors